Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation
Stroke2015Vol. 46(9), pp. 2555–2561
Citations Over TimeTop 10% of 2015 papers
Abstract
Our findings suggest that standard-dose NOACs were more effective and safer in Asians than in non-Asians, whereas low-dose NOACs performed similarly in both populations.
Related Papers
- → Expanding use of new oral anticoagulants(2014)17 cited
- → Practical management of new oral anticoagulants after total hip or total knee arthroplasty(2013)14 cited
- → Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery(2015)5 cited
- → Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Non-Valvular Atrial Fibrillation(2016)4 cited
- → HOSPITAL READMISSIONS AMONG PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH THE NEW ORAL ANTICOAGULANTS, APIXABAN, DABIGATRAN, AND RIVAROXABAN(2016)